The study suggests that BBR may overcome anti-PD-L1 antibody monotherapy resistance by down-regulating M2 macrophage marker expression in the TIME, further enhancing cytotoxic CD8+ T cell function, thereby promoting antitumor immunity and inhibiting tumor growth. This evidence concerns the gene CD8A and neoplasm.